Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Jones

Showing results (451-460 of 3,663) with videos related to

Pageof 367
Sort By:
International Journal of Antimicrobial Agents|January 25, 2005
Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilliHelio S Sader, Ronald N Jones
Biochemical and Biophysical Research Communications|August 18, 2004
Activation of plasminogen by Streptococcus mutansMicheala N Jones, Robert G Holt
The Journal of Antimicrobial Chemotherapy|April 1, 1992
Alternative antimicrobial agents to contemporary treatment of infections caused by Corynebacterium parvum (Propionibacterium acnes)J L Croco, R N Jones
Journal of Clinical Microbiology|May 1, 1992
Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporinR N Jones, M E Erwin
Advances in Skin & Wound Care|April 5, 2008
Does the proximity of an amputation, length of time between foot ulcer development and amputation, or glycemic control at the time of amputation affect the mortality rate of people with diabetes who undergo an amputation?Richard N Jones, William P Marshall
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 1, 1997
CQ-397 and CQ-414: antimicrobial activity and spectrum of two fluoroquinolone---cephalosporin, dual-action compounds with carboxamido bondsDavid M. Johnson, Ronald N. Jones
Diagnostic Microbiology and Infectious Disease|October 29, 1998
In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study GroupR N Jones, M E Erwin
Anaesthesia|November 3, 1998
Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesiaS T Vaughan, G N Jones
Diagnostic Microbiology and Infectious Disease|February 1, 1996
Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolatesM S Barrett, R N Jones
Journal of Clinical Microbiology|February 13, 1999
Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study GroupM E Erwin, R N Jones
Pageof 367

Showing results (451-460 of 3,663) with videos related to

Sort By:
Pageof 367
International Journal of Antimicrobial Agents|January 25, 2005
Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilliHelio S Sader, Ronald N Jones
Biochemical and Biophysical Research Communications|August 18, 2004
Activation of plasminogen by Streptococcus mutansMicheala N Jones, Robert G Holt
The Journal of Antimicrobial Chemotherapy|April 1, 1992
Alternative antimicrobial agents to contemporary treatment of infections caused by Corynebacterium parvum (Propionibacterium acnes)J L Croco, R N Jones
Journal of Clinical Microbiology|May 1, 1992
Preliminary disk diffusion susceptibility testing criteria for cefdaloxime (RU29246, HR-916 metabolite), a new orally administered cephalosporinR N Jones, M E Erwin
Advances in Skin & Wound Care|April 5, 2008
Does the proximity of an amputation, length of time between foot ulcer development and amputation, or glycemic control at the time of amputation affect the mortality rate of people with diabetes who undergo an amputation?Richard N Jones, William P Marshall
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|June 1, 1997
CQ-397 and CQ-414: antimicrobial activity and spectrum of two fluoroquinolone---cephalosporin, dual-action compounds with carboxamido bondsDavid M. Johnson, Ronald N. Jones
Diagnostic Microbiology and Infectious Disease|October 29, 1998
In vitro susceptibility testing and quality control parameters for sarafloxacin (A-56620): a fluoroquinolone used for treatment and control of colibacillosis in poultry. Quality Control Study GroupR N Jones, M E Erwin
Anaesthesia|November 3, 1998
Systemic mastocytosis presenting as profound cardiovascular collapse during anaesthesiaS T Vaughan, G N Jones
Diagnostic Microbiology and Infectious Disease|February 1, 1996
Antimicrobial activity and spectrum of sparfloxacin tested against erythromycin-resistant Streptococcus pneumoniae isolatesM S Barrett, R N Jones
Journal of Clinical Microbiology|February 13, 1999
Studies to establish quality control ranges for SB-265805 (LB2030) when using National Committee for Laboratory Standards antimicrobial susceptibility test methods. Quality Control Study GroupM E Erwin, R N Jones
Pageof 367